
Long-Acting GLP-1RAs Lower Cardiovascular, Kidney Risks and Mortality in Type 2 Diabetes, Meta-Analysis Finds
UK: A systematic review and meta-analysis of randomized trials have highlighted the significant benefits of long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs), both injectable and oral, in individuals with type 2 diabetes (T2D). The findings …